Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 18/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2295872 | 1.00 | SCN9A (0.40) | SCN9ANPC1RAB9ASMN1; SMN2TAS1R3 | |
| SCHEMBL2295312 | 0.87 | TAS1R3 (0.47) | SCN9ATAS1R3TAS1R1TAS1R2 | |
| SCHEMBL2287312 | 0.84 | NPC1 (0.36) | SCN9ANPC1RAB9ASMN1; SMN2TAS1R3 | |
| SCHEMBL4248890 | 0.84 | TAS1R3 (0.46) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL2287310 | 0.84 | NPC1 (0.36) | SCN9ANPC1RAB9ASMN1; SMN2TAS1R3 | |
| SCHEMBL2285724 | 0.80 | TAS1R3 (0.52) | NPC1RAB9ASMN1; SMN2TAS1R3TAS1R1 | |
| SCHEMBL4248445 | 0.80 | TAS1R3 (0.41) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL1928339 | 0.80 | SCN9A (0.39) | SCN9ASCN5A | |
| SCHEMBL2292223 | 0.78 | NPC1 (0.47) | SCN9ANPC1RAB9ASCN5A | |
| SCHEMBL2290146 | 0.75 | DHODH (0.43) | SCN9ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999136-B2 | Amide compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-16 | — | — | US | disclosed |
| US-7999136-B2 | Amide compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-16 | — | — | US | disclosed |
| US-7999136-B2 | Amide compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20100056640-A1 | AMIDE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056640-A1 | AMIDE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056640-A1 | AMIDE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2143709-A1 | AMIDE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2010-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056640-A1 | AMIDE COMPOUND AND USE THEREOF | NAT1, AGXT, HAX1 | SCN9A 1038/4885NPC1 435/4885RAB9A 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.